CN1989103A - 作为nmda受体拮抗剂的吲哚－2－甲脒衍生物 - Google Patents

作为nmda受体拮抗剂的吲哚－2－甲脒衍生物 Download PDF

Info

Publication number
CN1989103A
CN1989103A CNA2005800247658A CN200580024765A CN1989103A CN 1989103 A CN1989103 A CN 1989103A CN A2005800247658 A CNA2005800247658 A CN A2005800247658A CN 200580024765 A CN200580024765 A CN 200580024765A CN 1989103 A CN1989103 A CN 1989103A
Authority
CN
China
Prior art keywords
formula
indole
carboxamidine
meanings
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800247658A
Other languages
English (en)
Chinese (zh)
Inventor
I·博尔扎
C·霍瓦特
S·福尔考什
J·纳吉
S·科洛科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HUANGARY GIRUI GYOGYSZERGYAR
Original Assignee
HUANGARY GIRUI GYOGYSZERGYAR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HUANGARY GIRUI GYOGYSZERGYAR filed Critical HUANGARY GIRUI GYOGYSZERGYAR
Publication of CN1989103A publication Critical patent/CN1989103A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
CNA2005800247658A 2004-07-29 2005-07-21 作为nmda受体拮抗剂的吲哚－2－甲脒衍生物 Pending CN1989103A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP0401523 2004-07-29
HU0401523A HUP0401523A3 (en) 2004-07-29 2004-07-29 Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them

Publications (1)

Publication Number Publication Date
CN1989103A true CN1989103A (zh) 2007-06-27

Family

ID=89985408

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800247658A Pending CN1989103A (zh) 2004-07-29 2005-07-21 作为nmda受体拮抗剂的吲哚－2－甲脒衍生物

Country Status (21)

Country Link
US (1) US20090048303A1 (enExample)
EP (1) EP1773770B1 (enExample)
JP (1) JP2008508248A (enExample)
KR (1) KR20070038502A (enExample)
CN (1) CN1989103A (enExample)
AP (1) AP2006003840A0 (enExample)
AT (1) ATE427299T1 (enExample)
AU (1) AU2005266160A1 (enExample)
BR (1) BRPI0513932A (enExample)
CA (1) CA2574155A1 (enExample)
DE (1) DE602005013675D1 (enExample)
EA (1) EA009981B1 (enExample)
GE (1) GEP20094606B (enExample)
HU (1) HUP0401523A3 (enExample)
IL (1) IL179485A0 (enExample)
MA (1) MA28815B1 (enExample)
MX (1) MX2007001052A (enExample)
NO (1) NO20071109L (enExample)
TN (1) TNSN07016A1 (enExample)
WO (1) WO2006010965A1 (enExample)
ZA (1) ZA200700325B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402998A (zh) * 2010-11-18 2013-11-20 耶鲁大学 具有募集抗体并对人体免疫缺陷病毒进入有抑制活性的双功能分子
CN104334548A (zh) * 2012-05-22 2015-02-04 奥蒂福尼疗法有限公司 作为kv3抑制剂的乙内酰脲衍生物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
KR20120123089A (ko) 2010-02-16 2012-11-07 화이자 인코포레이티드 5-ＨＴ₄ 수용체의 부분 효능제인 (Ｒ)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조［ｄ］이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2Ｈ-피란-4-올
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
US11230541B2 (en) 2017-07-28 2022-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726388D0 (en) * 1997-12-12 1998-02-11 Cerebrus Ltd Chemical compounds
US6376530B1 (en) * 1999-05-10 2002-04-23 Merck & Co., Inc. Cyclic amidines useful as NMDA NR2B antagonists
US6319944B1 (en) * 1999-05-10 2001-11-20 Merck & Co., Inc. Aryl amidines, compositions containing such compounds and methods of use
GB0015488D0 (en) * 2000-06-23 2000-08-16 Merck Sharp & Dohme Therapeutic agents
HU227197B1 (en) * 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
JP2004253425A (ja) * 2003-02-18 2004-09-09 Tdk Corp 積層コンデンサ

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402998A (zh) * 2010-11-18 2013-11-20 耶鲁大学 具有募集抗体并对人体免疫缺陷病毒进入有抑制活性的双功能分子
CN107011333A (zh) * 2010-11-18 2017-08-04 耶鲁大学 具有募集抗体并对人体免疫缺陷病毒进入有抑制活性的双功能分子
CN103402998B (zh) * 2010-11-18 2017-09-26 耶鲁大学 具有募集抗体并对人体免疫缺陷病毒进入有抑制活性的双功能分子
CN107011333B (zh) * 2010-11-18 2021-03-19 耶鲁大学 具有募集抗体并对人体免疫缺陷病毒进入有抑制活性的双功能分子
CN104334548A (zh) * 2012-05-22 2015-02-04 奥蒂福尼疗法有限公司 作为kv3抑制剂的乙内酰脲衍生物

Also Published As

Publication number Publication date
DE602005013675D1 (de) 2009-05-14
TNSN07016A1 (en) 2008-06-02
KR20070038502A (ko) 2007-04-10
AP2006003840A0 (en) 2006-12-31
JP2008508248A (ja) 2008-03-21
WO2006010965A1 (en) 2006-02-02
NO20071109L (no) 2007-02-27
US20090048303A1 (en) 2009-02-19
MX2007001052A (es) 2007-04-16
ZA200700325B (en) 2008-05-28
CA2574155A1 (en) 2006-02-02
AU2005266160A1 (en) 2006-02-02
MA28815B1 (fr) 2007-08-01
BRPI0513932A (pt) 2008-05-20
HU0401523D0 (en) 2004-09-28
EP1773770A1 (en) 2007-04-18
EA200700365A1 (ru) 2007-06-29
ATE427299T1 (de) 2009-04-15
GEP20094606B (en) 2009-02-10
HUP0401523A3 (en) 2007-05-02
EA009981B1 (ru) 2008-04-28
EP1773770B1 (en) 2009-04-01
IL179485A0 (en) 2007-05-15
HUP0401523A2 (en) 2006-11-28

Similar Documents

Publication Publication Date Title
JP7612722B2 (ja) ＮＲ２ＢのＮ－アルキルアリール－５－オキシアリール－オクタヒドロ－シクロペンタ［ｃ］ピロールネガティブアロステリックモジュレーター
TWI511728B (zh) 包含非典型抗精神病藥物及taar1激動劑之醫藥組合
AU2014214326B2 (en) Substituted quinoxaline derivatives and their use as positive allosteric modulators of mGluR4
EP1773770B1 (en) Indole-2-carboxamidine derivatives as nmda receptor antagonists
JP4814880B2 (ja) 新規な４−ベンジリデン−ピペリジン誘導体
BR112013021549B1 (pt) Processos para preparação de forma cristalina anidra, para preparação de composição farmacêutica e para preparação de forma de dosagem, forma cristalina não solvatada anidra, composição farmacêutica, forma de dosagem, uso da referida forma cristalina e solvato
CN1989126A (zh) 新的杂环羧酸酰胺衍生物
CN113214140B (zh) 哌啶酰胺类衍生物、其药物组合物及其应用
EP3582783B1 (en) 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CN104955809B (zh) 取代的乙炔衍生物及其作为mGluR4的正变构调节剂的用途
CN1989127A (zh) 作为nr2b受体拮抗剂的犬尿烯酸酰胺衍生物
JPWO2005079845A1 (ja) 片頭痛予防薬
CN102869658B (zh) 脂肪酸酰胺水解酶的调节剂
Stec et al. Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists
TW434230B (en) 5-aminoethoxy-1,4-dihydroquinoxaline-2,3-diones
TW541295B (en) A novel substituted alkylteraamine derivative for use as tachykinin antagonist
HK40073006A (en) N-alkylaryl-5-oxyheteroaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b
KR20080077646A (ko) 인지 손상을 치료하는데 유용한 인돌론 화합물
HK1181651A (en) Combinations comprising atypical antipsychotics and taar1 agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication